Cargando…
Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage
BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe X-linked progressive neurodegenerative disease characterized by loss of ambulation, cardiomyopathy, respiratory insufficiency, and early mortality. Few data are available that describe the direct medical costs among patients with DMD in the U...
Autores principales: | Klimchak, Alexa C, Szabo, Shelagh M, Qian, Christina, Popoff, Evan, Iannaccone, Susan, Gooch, Katherine L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391028/ https://www.ncbi.nlm.nih.gov/pubmed/34595954 http://dx.doi.org/10.18553/jmcp.2021.27.10.1426 |
Ejemplares similares
-
Characterizing the Occurrence of Key Clinical Milestones in Duchenne Muscular Dystrophy in the United States Using Real-World Data
por: Szabo, Shelagh M., et al.
Publicado: (2022) -
Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review
por: Szabo, Shelagh M., et al.
Publicado: (2019) -
The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review
por: Szabo, Shelagh M., et al.
Publicado: (2021) -
Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States
por: Klimchak, Alexa C., et al.
Publicado: (2023) -
Exploring the relationship between North Star Ambulatory Assessment and Health Utilities Index scores in Duchenne muscular dystrophy
por: Audhya, Ivana, et al.
Publicado: (2023)